Development of Novel Octanoyl Chitosan Nanoparticles for Improved Rifampicin Pulmonary Delivery: Optimization by Factorial Design
- 40 Downloads
Abstract
A novel hydrophobic chitosan derivative, octanoyl chitosan (OC) with improved organic solubility was synthesized, characterized, and employed for the preparation of rifampicin (Rif) encapsulated nanoparticle formulations for pulmonary delivery. OC was characterized to confirm acyl group substitution and cytotoxicity in A549 epithelial lung cells. OC nanoparticles were produced by the double emulsion solvent evaporation technique without cross-linking and characterized for particle size distribution, morphology, crystallinity, thermal stability, aerosol delivery, and drug release rate. OC was successfully synthesized with substitution degree of 44.05 ± 1.75%, and solubility in a range of organic solvents. Preliminary cytotoxicity studies of OC showed no effect on cell viability over a period of 24 h on A549 cell lines. OC nanoparticles were optimized using a 32 full factorial design. An optimized batch of OC nanoparticles, smooth and spherical in morphology, had mean hydrodynamic diameter of 253 ± 19.06 nm (PDI 0.323 ± 0.059) and entrapment efficiency of 64.86 ± 7.73% for rifampicin. Pulmonary deposition studies in a two-stage impinger following aerosolization of nanoparticles from a jet nebulizer gave a fine particle fraction of 43.27 ± 4.24%. In vitro release studies indicated sustained release (73.14 ± 3.17%) of rifampicin from OC nanoparticles over 72 h, with particles demonstrating physical stability over 2 months. In summary, the results confirmed the suitability of the developed systems for pulmonary delivery of drugs with excellent aerosolization properties and sustained-release characteristics.
KEY WORDS
octanoyl chitosan hydrophobic chitosan rifampicin factorial design tuberculosisNotes
Acknowledgements
The authors would like to thank Mr. David McCarthy (UCL) for SEM images.
Compliance with Ethical Standards
Conflict of Interest
The authors declare there is no conflict of interest.
Supplementary material
References
- 1.World Health Organization. Global TB control—epidemiology, strategy, financing. Programs and Projects: WHO Global Tuberculosis Report - 2017. 2016. (http://www.who.int/tb/publications/global_report/gtbr2015_executive_summary.pdf?ua=1) (Date accessed Dec. 2017).
- 2.Ishikawaa AA, Salazarb JV, Salinasc M, Gaitania CM, Nurkiewiczd T, Negretec GR, et al. Self-assembled nanospheres for encapsulation and aerosolization of rifampicin. RSC Adv. 2016;6(16):12959–63.CrossRefGoogle Scholar
- 3.Singh C, Koduri LV, Dhawale V, Bhatt TD, Kumar R, Grover V, et al. Potential of aerosolized rifampicin lipospheres for modulation of pulmonary pharmacokinetics and bio-distribution. Int J Pharm. 2015;495:627–32.CrossRefPubMedGoogle Scholar
- 4.Rawal T, Parmar R, Tyagi R, Butani S. Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis. Colloids Surf B Biointerfaces. 2017;154:321–30.CrossRefPubMedGoogle Scholar
- 5.González-Juarrero M, O'Sullivan MP. Optimization of inhaled therapies for tuberculosis: the role of macrophages and dendritic cells. Tuberculosis. 2011;91(1):86–92.CrossRefPubMedGoogle Scholar
- 6.Mansour HM, Rhee YS, Wu X. Nanomedicine in pulmonary delivery. Int J Nanomedicine. 2009;4:299–319.CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Menon JY, Ravikumar P, Pise A, Gyawali D, Hsia CCW, Nguyen KT. Polymeric nanoparticles for pulmonary protein and DNA delivery. Acta Biomater. 2014;10:2643–52.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Efiana NA, Mahmood A, Lam HT, Zupančič O, Leonaviciute G, Bernkop-Schnürch A. Improved mucoadhesive properties of self-nanoemulsifying drug delivery systems (SNEDDS) by introducing acyl chitosan. Int J Pharm. 2017;519(1–2):206–12.CrossRefPubMedGoogle Scholar
- 9.Moschos SA, Bramwell VW, Somavarapu S, Alpar HO. Comparative immunomodulatory properties of a chitosan-MDP adjuvant combination following intranasal or intramuscular immunisation. Vaccine. 2005;23(16):1923–30.CrossRefPubMedGoogle Scholar
- 10.Grenha A, Seijo B, Remuñán-López C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci. 2005;25(4–5):427–37.CrossRefPubMedGoogle Scholar
- 11.Li HY Seville PC. Novel pMDI formulations for pulmonary delivery of proteins. Int J Pharm. 2010;385:73–8.CrossRefPubMedGoogle Scholar
- 12.Amidi M, Romeijn SG, Verhoef JC, Junginger HE, Bungener L, Huckriede A, et al. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. Vaccine. 2007;25(1):144–53.CrossRefPubMedGoogle Scholar
- 13.Motiei M, Kashanian S. Novel amphiphilic chitosan nanocarriers for sustained oral delivery of hydrophobic drugs. Eur J Pharm Sci. 2017;99:285–91.CrossRefPubMedGoogle Scholar
- 14.Huang Y, Yu H, Guo L, Huang Q. Structure and self-assembly properties of a new chitosan-based amphiphile. J Phys Chem B. 2010;114(23):7719–26.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Mourya VK, Inamdar NN. Chitosan modifications and application: opportunities galore. React Funct Polym. 2008;68:1013–51.CrossRefGoogle Scholar
- 16.Zhang J, Chen XG, Li YY, Liu CS. Self-assembled nanoparticles based on hydrophobically modified chitosan as carriers for doxorubicin. Nanomedicine. 2007;3(4):258–65.CrossRefPubMedGoogle Scholar
- 17.Cho Y, Kim TJ, Park HJ. Size-controlled self-aggregated N-acyl chitosan nanoparticles as a vitamin C carrier. Carbohydr Polym. 2012;88(3):1087–92.CrossRefGoogle Scholar
- 18.Cho Y, Kim TJ, Park HJ. Preparation, characterization, and protein loading properties of N-acyl chitosan nanoparticles. J Appl Polym Sci. 2012;124:1366–71.CrossRefGoogle Scholar
- 19.Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemoth. 2003;52:981–6.CrossRefGoogle Scholar
- 20.Holzer M, Vogel V, Mäntele W, Schwartz D, Haase W, Langer K. Physico-chemical characterisation of PLGA nanoparticles after freeze-drying and storage. Eur J Pharm Biopharm. 2009;72:428–37.CrossRefPubMedGoogle Scholar
- 21.Bolton S, Charles S. Pharmaceutical statistics. New York: Marcel Dekker Inc; 2004. p. 249–55.Google Scholar
- 22.Benetton SA, Kedor-Hackmann ERM, Santoro MIRM, Borges VM. Visible spectrophotometric and first-derivative UV spectrophotometric determination of rifampicin and isoniazid in pharmaceutical preparations. Talanta. 1998;47(3):639–43.CrossRefPubMedGoogle Scholar
- 23.European Directorate for the Quality of Medicines, European Pharmacopoeia 9.0 (Ph. Eur. 9th Edn.), Method Chapter 2.9.18, Preparations for inhalation: aerodynamic assessment of fine particles. 2017. Pg. No. 323 (Strasbourg, Council of Europe).Google Scholar
- 24.Liu J, Gonga T, Fu H, Wang C, Wang X, Chena Q, et al. Solid lipid nanoparticles for pulmonary delivery of insulin. Int J Pharm. 2008;356:333–44.CrossRefPubMedGoogle Scholar
- 25.Marques MRC, Loebenberg R, Almukainzi M. Simulated biological fluids with possible application in dissolution testing. Dissolut Technol. 2011;18:15–28.CrossRefGoogle Scholar
- 26.Tatarczak M, Flieger J, Szumilo H. High-performance liquid-chromatographic determination of rifampicin in complex pharmaceutical preparation and in serum mycobacterium tuberculosis-infected patients. Acta Pol Pharm Drug Res. 2005;62(4):251–6.Google Scholar
- 27.Kroll A, Dierker C, Rommel C, Hahn D, Wohlleben W, Schulze-Isfort S, et al. Cytotoxicity screening of 23 engineered nanomaterial using a test matrix of ten cell lines and three different assays. Part Fibre Toxicol. 2011;8:9.CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Grenha A. Chitosan nanoparticles: a survey of preparation methods. J Drug Target. 2012;20(4):291–300.CrossRefPubMedGoogle Scholar
- 29.Aranaz I, Harris R, Heras A. Chitosan amphiphilic derivatives. Chemistry and applications. Curr Org Chem. 2010;14:308–30.CrossRefGoogle Scholar
- 30.Li Y, Zhang S, Meng X, Chen X, Ren G. The preparation and characterization of a novel amphiphilic oleoyl-carboxymethyl chitosan self-assembled nanoparticles. Carbohydr Polym. 2011;83:130–6.CrossRefGoogle Scholar
- 31.Hu L, Suna Y, Wu Y. Advances in chitosan-based drug delivery vehicles. Nano. 2013;5:3103.Google Scholar
- 32.Shah PP, Mashru RC, Rane YM, Thakkar A. Design and optimization of mefloquine hydrochloride microparticles for bitter taste masking. AAPS PharmSciTech. 2008;9(2):377–89.CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Doan TVP, Couet W, Olivier JC. Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery. Int J Pharm. 2011;414:112–7.CrossRefPubMedGoogle Scholar
- 34.Bhavsar MD, Tiwari SB, Amiji MM. Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. J Control Release. 2006;110(2):422–30.CrossRefPubMedGoogle Scholar
- 35.Murakami H, Kobayashi M, Takeuchi H, Kawashima Y. Preparation of poly(DL-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int J Pharm. 1999;187:143–52.CrossRefPubMedGoogle Scholar
- 36.Kirby DJ, Rosenkrands I, Agger EM, Andersen P, Coombes AG, Perrie Y. PLGA microspheres for the delivery of a novel subunit TB vaccine. J Drug Target. 2008;16(4):282–93.CrossRefPubMedGoogle Scholar
- 37.Bilati U, Allémann, Doelker E. Poly(D,L-lactide-co-glycolide) protein-loaded nanoparticles prepared by the double emulsion method—processing and formulation issues for enhanced entrapment efficiency. J Microencapsul. 2009;22(2):205–14.CrossRefGoogle Scholar
- 38.Alex R, Bodmeier R. Encapsulation of water-soluble drugs by a modified solvent evaporation method. I. Effect of process and formulation variables on drug entrapment. J Microencapsul. 1990;7:347–55.CrossRefPubMedGoogle Scholar
- 39.Conway BR, Alpar HO. Double emulsion microencapsulation of proteins as model antigens using polylactide polymers: effect of emulsifier on the microsphere characteristics and release kinetics. Eur J Pharm Biopharm. 1996;42:42–8.Google Scholar
- 40.Yang YY, Chung TS, Ng N. Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomaterials. 2011;22:231–41.CrossRefGoogle Scholar
- 41.Atkins TW, Peacock J. The incorporation and release of bovine serum albumin from poly-hydroxybutyratehydroxyvalerate microcapsules. J Microencapsul. 1996;13:709–17.CrossRefPubMedGoogle Scholar
- 42.Jeffery H, Davis SS, O’Hagan DT. The preparation and characterization of poly(lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique. Pharm Res. 1993;10:362–8.CrossRefPubMedGoogle Scholar
- 43.Ranjan AP, Mukerjee A, Helson L, Vishwanatha JK. Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy. J Nanobiotechnol. 2012;10:38.CrossRefGoogle Scholar
- 44.Lubben IMV, Verhoef JC, Borchard G, Junginger HE. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci. 2001;14:201–7.CrossRefPubMedGoogle Scholar
- 45.Harleman DRF, Murcott SE. Method of drinking water treatment with natural cationic polymers, US 5543056 A. 1996, Aug 6.Google Scholar
- 46.Manca ML, Mourtas S, Dracopoulos V, Fadda AM, Antimisiaris SG. PLGA, chitosan or chitosan-coated PLGA microparticles for alveolar delivery? A comparative study of particle stability during nebulization. Colloids Surf B: Biointerfaces. 2008;62:220–31.CrossRefPubMedGoogle Scholar
- 47.NIST/SEMATECH e-Handbook of Statistical Methods, http://www.itl.nist.gov/div898/handbook/, date (accessed June 2013), (http://www.itl.nist.gov/div898/handbook/pri/section5/pri5322.htm).
- 48.Ma G, Yang D, Zhou Y, Xiao M, Kennedy JF, Nie J. Preparation and characterization of water-soluble N-alkylated chitosan. Carbohydr Polym. 2008;74:121–6.CrossRefGoogle Scholar
- 49.Zong Z, Kimura Y, Takahashi M, Yamane H. Characterization of chemical and solid state structures of acylated chitosans. Polymer. 2000;41:899–906.CrossRefGoogle Scholar
- 50.Parlati C, Colombo P, Buttini F, Young PM, Adi H, Ammit AJ, et al. Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency. Pharm Res. 2009;26(5):1084–92.CrossRefPubMedGoogle Scholar
- 51.Kendrick AH, Smith EC, Denyer J. EditorialNebulizers—fill volume, residual volume and matching of nebulizer to compressor. Respir Med. 1995;89:157–l59.CrossRefPubMedGoogle Scholar
- 52.Elhissi A. Liposomes for pulmonary drug delivery: the role of formulation and inhalation device design. Curr Pharm Des. 2017;23(3):362–72.PubMedGoogle Scholar
- 53.Klariæ D, Hafner A, Zubèiæ S, Dürrigl M, Filipoviæ-Grèiæ J. Spray-dried microspheres based on chitosan and and lecithin cyclosporin a delivery system. Chem Biochem Eng Q. 2012;26(4):355–64.Google Scholar
- 54.Costa P, Lobo J. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123–33.CrossRefPubMedGoogle Scholar
- 55.Lv H, Zhang S, Wang B, Cui S, Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Cont Rel. 2006;114:100–9.CrossRefGoogle Scholar
- 56.Hoskins C, Cuschieri A, Wang L. The cytotoxicity of polycationic iron oxide nanoparticles: common endpoint assays and alternative approaches for improved understanding of cellular response mechanism. J Nanobiotechnology. 2012;10:15.CrossRefPubMedPubMedCentralGoogle Scholar
- 57.Seydoux E, Rodriguez-Lorenzo L, RAM B, et al. Pulmonary delivery of cationic gold nanoparticles boost antigen-specific CD4 + T cell proliferation. Nanomedicine. 2016;12:1815–26.CrossRefPubMedGoogle Scholar